TOP > 外国特許検索 > THERAPEUTIC AGENT FOR NEUROPATHY IN ORGANIC ACIDEMIA OF WHICH MECHANISM RELIES ON INCREASE IN CAMP

THERAPEUTIC AGENT FOR NEUROPATHY IN ORGANIC ACIDEMIA OF WHICH MECHANISM RELIES ON INCREASE IN CAMP NEW

外国特許コード F180009462
整理番号 (S2017-0043-N0)
掲載日 2018年7月31日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP037507
国際公開番号 WO 2018074463
国際出願日 平成29年10月17日(2017.10.17)
国際公開日 平成30年4月26日(2018.4.26)
優先権データ
  • 特願2016-203955 (2016.10.17) JP
発明の名称 (英語) THERAPEUTIC AGENT FOR NEUROPATHY IN ORGANIC ACIDEMIA OF WHICH MECHANISM RELIES ON INCREASE IN CAMP NEW
発明の概要(英語) [Problem] To elucidate a mechanism associated with neuropathy in methylmalonic acidemia, and to develop a novel therapeutic agent or the like for neuropathy in organic acidemia on the basis of this finding. [Solution] The present inventors have established techniques for the establishment of iPS cells from a methylmalonic acidemia patient, for the establishment of a culturing method for stably maintaining the iPS cells, and for the differentiation of iPS cells from a methylmalonic acidemia patient into nerve cells, by using peripheral blood lymphocytes from a methylmalonic acidemia patient. It is found that neuropathy in organic acidemia can be treated and prevented by replenishing cAMP by employing the series of experimental techniques. A medicine according to the present invention is characterized by being capable of increasing cAMP in organic acidemia to treat or prevent neuropathy.
特許請求の範囲(英語) [claim1]
1. In viremia organic acid, thereby increasing cAMP, preventing a neurological disorder and not a medicament for the treatment of neurological disorders
[claim2]
2. Further, CREB activating according to claim 1 characterized in that the medicament for the treatment of neurological disorders
[claim3]
3. The organic acid viremia, Adnylate cyclase activity of a therapeutic agent according to claim 1 or 2 Neuronopathies
[claim4]
4. The organic acid viremia, viremia methylmalonic acid, propionic acid viremia selected from any one or more of a therapeutic agent according to claim 1 or 2 Neuronopathies
[claim5]
5. CAMP, Forskolin,GW9508,NECA,SKF77434,nicotinamide, dobutamine,db-cAMP increase made by any one of 4 and any claim 1 from a medicament for the treatment of neurological disorder
[claim6]
6. Increased cAMP, Adenylate cyclase to suppress or prevent a loss in the activity of which is performed by the characterized in that the therapeutic agent according to claim 3 Neuronopathies
[claim7]
7. The prevention and treatment of neurological disorders by not, and to increase the survival benefit from any one of claims 6 claim 1 medicament for the treatment of neurological disorder
[claim8]
8. Using a medicament for the treatment according to any one of claims 1-7 Neuronopathies, viremia neurological disorder in an organic acid and not ETI.HI
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KUMAMOTO UNIVERSITY
  • 発明者(英語)
  • MATSUMOTO SHIRO
  • ERA TAKUMI
  • ENDO FUMIO
国際特許分類(IPC)
指定国 (WO201874463)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接ご連絡ください。

PAGE TOP

close
close
close
close
close
close